Your browser doesn't support javascript.
loading
Rational combination of SHP2 and mTOR inhibition for the treatment of hepatocellular carcinoma.
Mulero-Sánchez, Antonio; Ramirez, Christel F A; du Chatinier, Aimée; Wang, Hui; Koomen, Sofie J I; Song, Ji-Ying; de Groot, Marnix H P; Lieftink, Cor; Bosma, Astrid; Burylo, Artur; van Tellingen, Olaf; Beijersbergen, Roderick L; Wang, Cun; Akkari, Leila; Bernards, René; Mainardi, Sara.
Afiliación
  • Mulero-Sánchez A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Ramirez CFA; Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • du Chatinier A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wang H; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China.
  • Koomen SJI; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Song JY; Department of Experimental Animal Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • de Groot MHP; Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Lieftink C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Bosma A; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Burylo A; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • van Tellingen O; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Beijersbergen RL; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Wang C; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Akkari L; State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, China.
  • Bernards R; Division of Tumor Biology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Mainardi S; Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Mol Oncol ; 17(6): 964-980, 2023 Jun.
Article en En | MEDLINE | ID: mdl-36650715
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Mol Oncol Asunto de la revista: BIOLOGIA MOLECULAR / NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Países Bajos